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More than 97% of patients diagnosed with small cell lung
cancer (SCLC) present with very advanced loco-regional
and often systemic involvement, a group of patients in
whom surgery has no role to play save the odd case where
the surgeon may be asked to provide additional tissue to
confirm the diagnosis. Less than 3% of SCLC patients
however will be diagnosed at an early stage (N0–N1) and
the role of surgery in these unusual SCLC patients remains
underutilized.
Over the years, many small series, mostly retrospective,
have shown excellent survival for stage I SCLC patients
who were treated surgically. Though in many cases these
individuals had undergone resection without a diagnosis of
SCLC histology prior to surgery, the fact has repeatedly
remained that this very small sub-population of SCLC
patients do very well after good surgery combined with,
since the late 1970s, adjuvant cisplatin based chemotherapy.
In many centers however, chemoradiation therapy alone
remains the only option offered.
In the absence of randomized studies evaluating the best
local modality to treat these rare early stage tumors, case
series and small phase II studies have historically guided us
in their management. Wakeam et al. now provide us with a
propensity-matched analysis of survival where the strategy
of surgery and adjuvant chemotherapy was compared
to that of chemoradiation therapy for the treatment of
early and locally advanced SCLC (1). The surgical cohort
identified represented 1.3% of all SCLC registered in the
US National Cancer Data Base in between 2004 and 2013:
2,089 surgical patients, 1,310 with clinical stage I, 335
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clinical stage II and 401 with clinical stage III.
This analysis confirmed nearly a double in median
overall survival for N0 patients treated with surgery: 38 vs.
22 months. Their analysis also showed that the benefits of
surgery were only seen when an R0 resection was achieved,
that lobectomy was superior to sublobar resections and to
pneumonectomies and that adjuvant chemotherapy should
be considered after these R0 resections. These findings had
all been hinted previously in smaller published series or
non-randomized prospective trials, the size of the cohorts
reported here re-enforces these principles.
From my point of view, in 2017, despite the absence
of phase III randomized trials, it is more than reasonable
to offer primary resection to these patients as strongly
suggested by the results of this analysis. These patients
however should all get invasive mediastinal staging and
brain imaging upfront. We have reported previously that
there is a significant discrepancy in between clinical and
pathological staging in these patients with 20% of clinical
stage I–II patients being upstaged as well as up to one
third of clinical stage III patients being downstaged after
resection (2).
As suggested by the observations of Wakeam et al., the
extent of resection should probably be at least a lobectomy,
though in patients with limited pulmonary reserves for
which tumor an anatomical segmentectomy is feasible,
without oncological compromise, such an anatomical limited
resection may possibly be a good option. The role of surgery
when a pneumonectomy is required is probably very limited.
Whatever the size of the lesion, even with pN0 disease,
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adjuvant chemotherapy should be considered standard
of care for all resected SCLC patients. The role of postoperative radiation therapy is less well defined and our
approach has been to offer it sequentially to chemotherapy
in most patients with resected pN+ disease, any pN+
involvement, even when an R0 resection was achieved.
SCLC is usually associated with a very rapid growth
rate and early dissemination to regional lymph nodes and
distant sites. Are these early SCLCs a biologically distinct
population despite apparent similar histology? There may
be some merit in pooling our limited banked resected
SCLC to evaluate their genetic make-up and evaluate
whether genomics could help us better identify those in
whom surgery should be considered in the future.
The surgical cohort studied by Wakeam et al. was
collected in between 2004 and 2013. It is humbling to
note that the survivals we reported after surgery for SCLC
collected one decade earlier by the International Association
for the Study of Lung Cancer (IASLC) Lung Cancer
Staging Project had very similar survivals of around 55% for
resected pathological stages I SCLC, 40% for pathological
stage II and 12% for pathological stage III.
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